UPDATE: JPMorgan Downgrades ObsEva (OBSV) to Underweight on Continued Cash Woes into PRIMROSE Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
ObsEva appoints Brian O’Callaghan as Chief Executive Officer
November 9, 2020 1:00 AM ESTÂ
Geneva, Switzerland and Boston, MA November 9, 2020 ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health today announced that ObsEvas Board of Directors has appointed Brian OCallaghan, to succeed Dr Ernest Loumaye, as Chief Executive Officer and member of the companys Executive Committee, effective 1 December 2020. He will also be proposed for election on ObsEvas Board of Directors at next company AGM.
As ObsEva evolves from a development company towards commercialization, Dr Ernest Loumaye,... More
ObsEva Announces Third Quarter 2020 Financial Results and Business Update
November 5, 2020 1:00 AM ESTPositive Phase 3 PRIMROSE 1 and 2 trial results of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids presented in late breaking session of ASRM Virtual CongressLinzagolix regulatory submissions planned for Q4:20/H1:21 in Europe/U.S.Actively discussing commercial partnership to maximize linzagolix best-in-class... More
ObsEva Announces Third Quarter 2020 Financial Results and Business Update
November 5, 2020 1:00 AM ESTPositive Phase 3 PRIMROSE 1 and 2 trial results of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids presented in late breaking session of ASRM Virtual CongressLinzagolix regulatory submissions planned for Q4:20/H1:21 in Europe/U.S.Actively discussing commercial partnership to maximize linzagolix best-in-class... More
